About MedAssets (NASDAQ:MDAS)
MedAssets, Inc. (MedAssets) provides technology-enabled products and services to healthcare organizations, including hospitals, health systems, non-acute healthcare providers, payers, other service providers and product manufacturers. The Company operates its business through two business segments: Spend and Clinical Resource Management (SCM) and Revenue Cycle Management (RCM). The SCM segment delivers market insight, performance improvement advisory and cost management capabilities to healthcare providers. The RCM segment provides revenue cycle management solutions to healthcare providers, primarily hospitals and health systems. The Company's technology-enabled solutions are delivered through the Company-hosted software or software as a service (SaaS) or Web-based applications. Its Web-based applications employ cloud computing by using the Internet to deploy the Company's solutions across decentralized health care organizations, providing standardization and compliance.
Industry, Sector and Symbol:
- Industry: IT Services & Consulting
- Sub-Industry: Health Care Technology
- Sector: IT Services & Consulting - NEC
- Symbol: NASDAQ:MDAS
- CUSIP: 58404510
- Web: www.medassets.com
- Trailing EPS: ($0.59)
- Net Margins: -1.18%
- Return on Equity: -2.00%
- Return on Assets: -0.54%
- Outstanding Shares: 60,000,000
Frequently Asked Questions for MedAssets (NASDAQ:MDAS)
What is MedAssets' stock symbol?
MedAssets trades on the NASDAQ under the ticker symbol "MDAS."
How were MedAssets' earnings last quarter?
MedAssets, Inc. (NASDAQ:MDAS) announced its earnings results on Wednesday, July, 29th. The technology company reported $0.31 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.27 by $0.04. The technology company earned $190.40 million during the quarter, compared to the consensus estimate of $187.45 million. MedAssets had a negative return on equity of 2.00% and a negative net margin of 1.18%. The business's quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.30 EPS. View MedAssets' Earnings History.
Who are some of MedAssets' key competitors?
Some companies that are related to MedAssets include International Business Machines Corporation (IBM), Accenture plc (ACN), Vmware (VMW), Automatic Data Processing (ADP), Cognizant Technology Solutions Corporation (CTSH), NetEase (NTES), Infosys Limited (INFY), Wipro Limited (WIT), CGI Group (GIB), Total System Services (TSS), VeriSign (VRSN), Gartner (IT), IMS Health Holdings (IMS), CDW Corporation (CDW), Qihoo 360 Technology Co Ltd (QIHU), Akamai Technologies (AKAM), Amdocs Limited (DOX) and GoDaddy (GDDY).
How do I buy MedAssets stock?
Shares of MedAssets can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MedAssets' stock price today?
One share of MedAssets stock can currently be purchased for approximately $31.35.
How can I contact MedAssets?
MedAssets' mailing address is 100 N Point Ctr E Ste 200, ALPHARETTA, GA 30022-8261, United States. The technology company can be reached via phone at +1-678-3232500.
MarketBeat Community Rating for MedAssets (NASDAQ MDAS)MarketBeat's community ratings are surveys of what our community members think about MedAssets and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for MedAssets (NASDAQ:MDAS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for MedAssets (NASDAQ:MDAS)
Analysts' Ratings History for MedAssets (NASDAQ:MDAS)
(Data available from 11/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|1/27/2016||William Blair||Reiterated Rating||Market Perform||N/A|
|1/25/2016||Canaccord Genuity||Reiterated Rating||Hold||N/A|
|11/20/2015||Leerink Swann||Reiterated Rating||Hold||$22.00 -> $31.35||N/A|
Earnings History and Estimates Chart for MedAssets (NASDAQ:MDAS)
Earnings History by Quarter for MedAssets (NASDAQ MDAS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2015||Q315||$0.28||$0.27||$187.34 million||$117.20 million||View||N/A|
|7/29/2015||Q2||$0.27||$0.31||$187.45 million||$190.40 million||View||Listen|
|4/29/2015||Q115||$0.30||$0.31||$184.33 million||$185.58 million||View||N/A|
|2/17/2015||Q414||$0.39||$0.39||$195.00 million||$198.20 million||View||N/A|
|10/29/2014||Q314||$0.31||$0.34||$172.50 million||$175.70 million||View||Listen|
|7/30/2014||Q214||$0.29||$0.30||$175.70 million||$175.42 million||View||Listen|
|4/30/2014||Q114||$0.29||$0.27||$172.30 million||$170.87 million||View||Listen|
|2/26/2014||Q413||$0.28||$0.30||$165.64 million||$170.50 million||View||Listen|
|7/31/2013||Q2 2013||$0.26||$0.30||$167.64 million||$170.70 million||View||N/A|
|5/1/2013||Q1 2013||$0.30||$0.41||$164.75 million||$172.84 million||View||N/A|
|2/20/2013||Q4 2012||$0.28||$0.27||$159.84 million||$163.80 million||View||N/A|
Earnings Estimates for MedAssets (NASDAQ:MDAS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for MedAssets (NASDAQ:MDAS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MedAssets (NASDAQ MDAS)
Insider Trades by Quarter for MedAssets (NASDAQ MDAS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/26/2015||John A Bardis||Director||Sell||2,000||$19.73||$39,460.00|| |
|2/24/2015||John A Bardis||Director||Sell||100,000||$19.45||$1,945,000.00|| |
|2/19/2015||R Halsey Wise||CEO||Buy||110,300||$18.15||$2,001,945.00|| |
|11/26/2014||Keith L Thurgood||Insider||Sell||5,681||$19.54||$111,006.74|| |
|11/12/2014||Harris Iv Hyman||Director||Sell||3,334||$20.50||$68,347.00|| |
|11/11/2014||John A Bardis||CEO||Sell||100,000||$20.02||$2,002,000.00|| |
|11/7/2014||John A Bardis||CEO||Sell||191,833||$20.74||$3,978,616.42|| |
|11/4/2014||John A Bardis||CEO||Sell||208,167||$21.48||$4,471,427.16|| |
|10/28/2014||Jonathan H Glenn||Insider||Sell||7,300||$22.62||$165,126.00|| |
|10/27/2014||Jonathan H Glenn||Insider||Sell||500||$22.50||$11,250.00|| |
|8/13/2014||Terrence J Mulligan||Director||Sell||1,000||$21.97||$21,970.00|| |
|7/10/2014||Terrence J Mulligan||Director||Sell||1,000||$21.97||$21,970.00|| |
|7/1/2014||Charles O Garner||CFO||Sell||3,167||$22.81||$72,239.27|| |
|6/12/2014||Terrence J Mulligan||Director||Sell||1,000||$23.30||$23,300.00|| |
|5/14/2014||Terrence Mulligan||Director||Sell||1,000||$22.93||$22,930.00|| |
|5/2/2014||R Halsey Wise||Director||Buy||8,950||$22.31||$199,674.50|| |
|4/10/2014||Terrence Mulligan||Director||Sell||1,000||$24.56||$24,560.00|| |
|3/13/2014||Terrence Mulligan||Director||Sell||1,000||$25.24||$25,240.00|| |
|2/28/2014||Charles Garner||CFO||Sell||8,949||$24.05||$215,223.45|| |
|2/24/2014||Terrence Mulligan||Director||Sell||1,000||$21.97||$21,970.00|| |
|1/16/2014||Charles Garner||CFO||Sell||15,207||$20.83||$316,761.81|| |
|1/16/2014||Terrence Mulligan||Director||Sell||2,000||$21.97||$43,940.00|| |
|11/26/2013||John Rutherford||Director||Sell||13,000||$21.41||$278,330.00|| |
|11/21/2013||Bruce Wesson||Director||Sell||60,263||$20.54||$1,237,802.02|| |
|11/15/2013||Terrence Mulligan||Director||Sell||1,000||$21.97||$21,970.00|| |
|11/8/2013||John Bardis||CEO||Sell||200,000||$22.04||$4,408,000.00|| |
|10/22/2013||Lance M Culbreth||CAO||Sell||2,000||$26.45||$52,900.00|| |
|10/8/2013||Terrence Mulligan||Director||Sell||1,000||$24.64||$24,640.00|| |
|9/17/2013||Terrence Mulligan||Director||Sell||1,000||$24.21||$24,210.00|| |
|9/11/2013||Lance M Culbreth||CAO||Sell||4,000||$24.23||$96,920.00|| |
|9/10/2013||Jonathan H Glenn||Insider||Sell||12,268||$24.00||$294,432.00|| |
|8/29/2013||Charles Garner||CFO||Sell||2,017||$23.02||$46,431.34|| |
|8/29/2013||Harris Iv Hyman||Director||Sell||3,199||$23.26||$74,408.74|| |
|8/26/2013||Harris Iv Hyman||Director||Sell||5,985||$23.50||$140,647.50|| |
|8/23/2013||C Piccolo||Director||Sell||17,487||$22.94||$401,151.78|| |
|8/23/2013||John Bardis||CEO||Sell||17,304||$23.04||$398,684.16|| |
|8/15/2013||John Bardis||CEO||Sell||10,000||$22.87||$228,700.00|| |
|8/14/2013||Terrence Mulligan||Director||Sell||5,000||$23.50||$117,500.00|| |
|8/9/2013||John Rutherford||Director||Sell||50,000||$23.62||$1,181,000.00|| |
|8/5/2013||Lance M Culbreth||CAO||Sell||22,866||$23.34||$533,692.44|| |
|8/2/2013||Gregory Strobel||Insider||Sell||4,025||$22.78||$91,689.50|| |
|8/2/2013||Terrence Mulligan||Director||Sell||29,446||$23.39||$688,741.94|| |
|7/23/2013||Michael Patrick Nolte||COO||Sell||20,000||$21.04||$420,800.00|| |
|7/17/2013||Lance M Culbreth||CAO||Sell||4,500||$20.45||$92,025.00|| |
|7/16/2013||Michael Patrick Nolte||COO||Sell||19,222||$19.63||$377,327.86|| |
|7/16/2013||Rand A Ballard||Insider||Sell||13,163||$20.00||$263,260.00|| |
|7/16/2013||Terrence J Mulligan||Director||Sell||55,000||$20.00||$1,100,000.00|| |
|5/10/2013||Lance M Culbreth||CAO||Sell||16,000||$18.54||$296,640.00|| |
|3/25/2013||Charles O Garner||CFO||Sell||15,038||$19.38||$291,436.44|| |
|11/27/2012||Gregory A Strobel||Insider||Sell||10,000||$16.24||$162,400.00|| |
|11/27/2012||John A Bardis||CEO||Sell||107,550||$16.51||$1,775,650.50|| |
|11/14/2012||John A Bardis||CEO||Sell||71,340||$16.34||$1,165,695.60|| |
Latest Headlines for MedAssets (NASDAQ MDAS)
MedAssets (NASDAQ MDAS) Chart for Sunday, November, 19, 2017